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Background: Previous studies have demonstrated that the initial hospital cost associated with endovascular aneurysm
repair (EVAR) is approximately $20,000.However, the cost of long-term surveillance and secondary procedures is poorly
characterized.
Methods: Between December 1998 and June 2006, 259 patients underwent EVAR for infrarenal aneurysms at a single
institution. Follow-up costs were calculated using a relative value unit based hospital cost accounting system, which
incorporates departmental direct and indirect costs. Institutional overhead costs were included using a conversion factor.
Costs for professional services were determined by a cost-to-charge ratio, and outpatient visits were calculated with a
time-based formula. Year 2006 costs were applied to prior years. To minimize costs associated with the early learning
curve, the initial 50 EVAR patients between December 1995 and 1998 were excluded. Patients with <1 year follow-up
were also excluded. Data are expressed as mean  standard error.
Results: The mean follow-up after EVAR for 136 patients was 34.7  1.8 months. The cumulative 5-year postplacement
cost per patient was $11,351. The 27 patients (19.9%) who required secondary procedures had a 5-year cumulative cost
of $31,696 compared with $3668 for 109 patients without secondary procedures (8.6-fold increase, P< .05). The 5-year
cost for patients with endoleak was $26,739 compared with $5706 for those without endoleak (4.7-fold increase, P <
.05). Overall, major cost components were 57.4% for secondary procedures and 32.5% for radiologic studies.
Conclusions:During a 5-year period, the postplacement cost of EVAR increases the global cost by 44%. The subgroups of
patients with endoleaks and those requiring secondary procedures generate a disproportionate share of postplacement
costs. Efforts at minimizing cost should emphasize technical and device modifications aimed at reducing endoleaks and
the need for secondary procedures. ( J Vasc Surg 2007;46:9-15.)Endovascular aneurysm repair (EVAR) offers the ad-
vantage of lower perioperative morbidity and mortality as
well as shorter hospital stay and operative time compared
with open repair.1,2 Nationwide, these clinical benefits have
translated into a trend, such that EVAR is often replacing
open repair of infrarenal abdominal aortic aneurysms
(AAA).3 During the past decade, EVAR has evolved into
the treatment of choice for elderly and high-risk patients
but is also frequently used in lower-risk patients with suit-
able anatomy.
EVAR has not been proven to reduce cost, however. A
number of cost-analysis studies have demonstrated that the
initial cost of EVAR exceeds that of open repair, despite a
shorter hospitalization and fewer early complications.4-8
This is largely the result of high endograft device costs.
Medicare reimbursement often fails to meet the hospital
expenses of EVAR.4,9 Hospitals and health care systems,
already struggling with escalating costs, may find financial
considerations further influencing their application of
EVAR.
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thusiasm for EVAR is tempered by long-term problems of
endoleak, migration, sac expansion, and even rupture. Vig-
ilant, lifelong follow-up is important to identify and correct
these complications. Rates of intervention for these techni-
cal and device-related failures have been up to 27%.10-12
Open AAA repairs do not have the same requirements for
long-term follow-up and require fewer late interventions
for graft related complications.13 As a result, the costs of
EVAR may continue to accumulate over time compared
with open AAA repair. The substantial costs associated with
long-term surveillance and secondary procedures have not
been well established. This study defines the long-term
expenses of EVAR and characterizes the specific compo-
nents and contributors to postplacement costs.
METHODS
Between December 1998 and June 2006, 259 consec-
utive patients underwent endovascular repair of infrarenal
aortic aneurysms at the Ochsner Clinic Foundation (OCF).
The first 50 patients, between December 1995 and 1998,
were excluded from this analysis to minimize increased
costs that could have been associated with the learning
curve in this cohort. A prospective database of all EVARs at
our institution has been maintained since 1997. This data-
base was queried and supplemented with medical records
to determine all radiologic studies, secondary procedures,
hospital readmissions, and outpatient visits that occurred
during the follow-up period. Thus, this is a retrospective
review of our prospectively maintained database.
9
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devices consists of an initial postoperative physical exam
and outpatient visit at 2 weeks, followed by four-view plain
abdominal radiographs (anteroposterior, lateral, 2 ob-
liques), computed tomography (CT) scan of the abdomen
and pelvis with 2.5-mm to 3-mm axial images, and addi-
tional outpatient visits at 1, 6, and 12 months, and yearly
thereafter. Patients treated in United States Food andDrug
Administration trials had no significant difference in sur-
veillance protocol except some required an immediate post-
operative CT. This CT was performed at the initial en-
dograft placement and, therefore, the associated extra cost
was excluded from this study. In patients with renal insuf-
ficiency, duplex ultrasonography is used in place of CT for
endograft surveillance.
Late endovascular secondary procedures usually reset
the follow-up timetable to 1, 6, 12 months, and yearly
thereafter. Although additional diagnostic studies and follow-
up were obtained at the discretion of the attending sur-
geon, the two attendings responsible for all of the implants
(W. C. S., S. R. M.) closely followed the established sur-
veillance protocol. To examine long-term costs, any patient
with 1-year follow-up at OCF was excluded.
Cost analysis. Institutional costs incurred directly
from patient care were accessed through OCF’s cost ac-
counting database (Eclipsys, Boca Raton, Fla). Costs of
preoperative evaluation, and initial endograft placement
with hospitalization, were not part of the present study.
The steps in our cost accounting system are briefly
described here. Direct expenses are first consolidated
monthly at a departmental (cost center) level and then are
classified by the cost components of labor, supply, equip-
ment, and facility. Next, components are divided into fixed
expenses independent of patient volume and variable ex-
penses dependent on patient volume. Individual patients
are assigned cost codes for every chargeable service or
supply item. Departmental managers and Hospital Deci-
sion Support then develop allocation statistics (relative
value units) for each component of every cost code so that
a final cost can be assigned. Individual patient costs are the
sum of costs from each department utilized. The average
cost calculations from January to June 2006 were used to
adjust prior years’ costs for the sake of data uniformity.
Professional fees were calculated by using department-
specific cost-to-charge ratios and were adjusted according
to the average January to June 2006 costs. Costs for out-
patient appointments were determined by using a time-
based formula. Patient appointments were categorized as
10, 20, and 30 minutes according to Evaluation and Man-
agement codes. Outpatient department expenses were then
allocated by the time coded for the follow-up appointment.
Overhead costs for the institution were added to the
direct costs by a factor of 30% for each patient. This factor
has been uniformly decided on by Hospital Decision Sup-
port and varies 1% to 2% monthly. This method allows for
equitable distribution among patients: those patients with
higher overall cost absorb more overhead cost. Overhead
expense includes costs from departments not directly in-volved in patient care (eg, housekeeping, computer tech-
nology, finance), equipment and facility depreciation, and
interest expense on borrowings.
All costs incurred after discharge from the original
EVAR were included in this study and will heretofore be
referred to as postplacement costs. These postplacement
costs were subdivided into outpatient visits, radiologic
studies, laboratory tests, secondary procedures, and hospi-
tal readmissions for complications of EVAR that did not
require a secondary procedure (eg, ischemic colitis). Radio-
logic costs consisted of CT scans, abdominal radiographs,
duplex ultrasonography, and vascular laboratory studies.
A secondary procedure was defined as any intervention
(including diagnostic angiograms) performed due to the
original aneurysm or for a complication of EVAR during
the follow-up period. Secondary procedure costs were fur-
ther broken down into cost of operating/interventional
suite (anesthesia, operating room time, professional fees,
nonendovascular surgical supply), endovascular supply,
room and board (recovery room, outpatient surgery, floor/
intensive care), pharmacy/laboratory, medical supply
(nonoperative supply costs), radiology, and miscellaneous
(respiratory care, dialysis, physical therapy, occupational
therapy).
Endoleak was defined as persistent blood flow outside
the endograft identified on an imaging study during follow-
up. The types of endoleak have been previously reported. 14,15
Indications for secondary interventions for endoleak were
the presence of a type I or type III endoleak, or a type II
endoleak with significant aneurysm sac expansion (5
mm). Translumbar glue embolization has been favored for
treatment of type II endoleaks in recent years, although
previously coil microembolization was used. Migration was
determined as10-mm caudal movement of the endograft
or any amount of migration resulting in symptoms or a
secondary procedure.
Statistical analysis. The data are expressed as mean
standard error. Cost comparisons between groups with and
without secondary interventions or endoleaks were made
with theWilcoxon two-sample test. P .05 was considered
statistically significant. Statistical analysis was performed by
using SAS 8.2 software (SAS Institute Inc, Cary, NC).
RESULTS
Patient cohort. Of 259 completed EVARs included
in the study period, 136 patients were included in the final
cost analysis. Reasons for exclusion were death in 35 pa-
tients, 1 year since EVAR in 33, 28 were lost to follow-
up, 15 had follow-up at another institution, and 12 patients
refused further treatment.
Complete follow-up with all required outpatient visits
and surveillance imaging was attained in 61 of the 136
included patients. An additional 60 patients missed one or
more outpatient visits or imaging studies during their follow-
up period, completing 81.1% of outpatient visits, 75.9%CT
or duplex ultrasonography, and 75.1% of abdominal radio-
graph sets. The remaining 15 patients had an interval of1
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which they resumed normal surveillance.
Baseline characteristics. Themean age of the patients
(87.5%men) was 73.2 0.6 years. Comorbidities included
the presence of coronary artery disease (58.8%), hyperten-
sion (57.4%), peripheral vascular disease (30.1%), chronic
obstructive pulmonary disease (27.9%), diabetes mellitus
(13.9%), and chronic renal insufficiency (12.5%). Spinal/
regional anesthesia was used in 80.9% of EVAR.
Modular bifurcated endografts were deployed in 130
patients. Endograft types were Zenith (Cook, Blooming-
ton, Ind) in 75, AneuRx (Medtronic/AVE Inc, Santa Rosa,
Calif) in 50, and Excluder (W.L. Gore & Assoc, Flagstaff,
Ariz) in five. The other six patients were treated with
endocuffs (AneuRx, n  5; Zenith, n  1) alone for
saccular aneurysms (n  4) and pseudoaneurysms (n  2).
Postplacement costs. The mean follow-up was 34.7
1.8 months. During the first postplacement year, patients
averaged 3.7  0.1 outpatient visits, 2.7  0.1 CT scans,
and 2.5 0.1 complete sets of abdominal radiographs. For
the subsequent years 2 through 5 of follow-up, the number
of yearly outpatient visits, CT scans, and abdominal radio-
graph sets averaged 1.2  0.04, 1.0  0.04, and 1.0 
0.03, respectively. Ultrasound studies (n  18) were used
selectively in place of surveillance CT scans in 10 patients
with renal insufficiency.
Mean postplacement cost was $2768  $556, $1435 
$428, $2205 $706, $1710 $610, and $3233 $1687
Fig 1. Yearly postplacement cost components. Laboratory costs
were 0.6% for all years.
Table I. Five-year cumulative postplacement cost
Follow-up year
All patients*
No. Mean cost
1 136 $2768  $556
2 98 $1435  $428
3 65 $2205  $706
4 47 $1710  $610
5 33 $3233  $1687
Cumulative cost $11,351
*Data are mean  standard error.
†Statistically significant (P  .05) vs no secondary intervention group.at 1, 2, 3, 4, and 5 years, respectively. Overall, the cumu-lative 5-year cost per patient was $11,351 (Table I). Post-
placement cost consisted of secondary procedures (57.4%),
radiologic studies (32.5%), outpatient visits (7.6%), related
hospital readmissions (2.1%), and laboratory costs (0.4%).
In the first year of follow-up, the largest cost component
was radiologic studies (Fig 1). For years 2, 3, 4, and 5,
secondary procedures accounted for most of the expenses.
Secondary procedures. Fifty-one secondary proce-
dures were performed in 27 patients (19.9%; Table II). The
mean time to secondary procedures was 25.4  1.0
months. Patients who underwent a secondary procedure at
any point during follow-up were also analyzed as a separate
group. Patients with secondary procedures had an 8.6-fold
increase in postplacement cost (Table I) compared with
patients not needing an additional intervention (P  .05).
Cost components for secondary procedures were operating/
interventional suite (41.1%), room and board (21.1%), endo-
vascular supply (18.2%), pharmacy/laboratory (10.2%),
medical supply (3.0%), radiology (1.5%), andmiscellaneous
(4.9%).
Themost common secondary procedure was a diagnostic
secondary procedure* Secondary procedure*
Mean cost No. Mean cost
$1635  $131 27 $7340  $2608†
$499  $21 23 $4490  $1695†
$458  $25 18 $6767  $2254
$523  $52 14 $4506  $1884†
$553  $77 11 $8593  $4796
$3668 $31,696†
Table II. Secondary procedures
Procedure No. Mean cost*
Endograft explant/EAB† 2 $57,681  $6464
Iliac limb placement/EC‡ 1 $29,479
Open conversion (delayed) 4 $21,382  $3130
Aortouniiliac device 1 $20,983
Iliac endocuff 6 $13,042  $2274
Endocuff 4 $8722  $2041
Femoral-femoral bypass 1 $8217
Laparoscopic IMA ligation 1 $8021
Thrombolysis 1 $7437
PTA  stent 2 $5153  $334
Translumbar glue embolization 3 $4850  $769
Coil microembolization 4 $4640  $458
Diagnostic angiogram 20 $2677  $378
Abscess drainage 1 $1507
EAB, Extra-anatomic bypass; EC, endocuff; IMA, inferior mesenteric artery;
PTA, percutaneous transluminal angioplasty.
*Data are mean  standard error.
†One procedure was staged, with the costs of both procedures combined.
‡Staged placement of iliac limb after the initial endograft device malfunc-
tioned.No
No.
109
75
47
33
22angiogram (n  20), performed in 13 patients (Fig 2, A).
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(n  13), endoleak identification (n  6), and endograft
limb thrombosis (n  1; Table III). The remaining 31
secondary procedures were performed for therapeutic rea-
sons (Table II). Proximal (n  4) and iliac (n   6) endo-
cuffs were placed for cases of endoleak (n  6), migration
(n  2), or both endoleak/migration (n  2). The mean
cost of an iliac endocuff procedure was $13,042  $2274
compared with $8722  $2041 for a proximal endocuff
procedure. The use of additional supplies with iliac endo-
cuffs was responsible for the increased expense of this
procedure.
Six delayed open conversions were required. Conver-
sions were due to endoleaks alone (type I, type III) in 2
patients, for endograft infection in 2, migration and en-
doleak (type I) in 1, and aneurysm expansion (endoten-
sion) in 1. Both open conversions for infection were
managed with extra-anatomic bypass and endograft ex-
plantation. The mean cost of open conversion alone was
Fig 2. A, Secondary procedures by frequency (%). B, Secondary
procedures by cost (%). PTA, Percutaneous transluminal angio-
plasty.$21,382  $3130, and the mean cost for open conversionwith extra-anatomic bypass was $57,681  $6464, the
highest for any of the secondary procedures. These six
conversions accounted for 41% of the secondary procedure
expense (Fig 2, B).
Related hospital admissions. Two patients required
a hospital readmission not associated with a secondary
procedure. One was admitted for ischemic colitis 5 days
after EVAR. The colitis resolved without operative inter-
vention, and the patient was discharged on hospital day 8
for a total cost of $12,264. The other patient was admitted
on two separate occasions with incisional postoperative
wound infections. The first occurred after EVAR and the
second after a delayed open conversion. The patient was
released from the hospital in good condition on both
occasions, with respective readmission costs of $1979 and
$3650.
Endoleaks. During the follow-up period, 27 patients
(19.9%) had 29 endoleaks (type I, n  5; type II, n  17;
type III, n 7). In 14 patients, 14 endoleaks were seen on
the 1-month postplacement CT; the remaining 15 en-
doleaks were detected later in follow-up. Eight endoleaks
(type II) weremonitored without any secondary procedure,
and seven have resolved to date at a mean of 7.7  1.1
months. In patients with endoleaks, 5-year cumulative
post-placement costs were 4.7-fold higher (Table IV) than
for patients without endoleak ($26,739 vs $5706; P .05).
DISCUSSION
In 2000, OCF reported a greater hospital cost for
Table III. Diagnostic angiograms
Patient Indications Findings
Additional
treatment
1 AAA growth None
AAA growth None
AAA growth None Delayed OC
2 EL identification None None
3 Endograft limb
thrombosis
Limb
occlusion
Femorofemoral
bypass
4 AAA growth Type II EL None
5 EL identification Type I EL EC
6 AAA growth Type II EL Embolization
7 AAA growth None Delayed OC
8 AAA growth None
AAA growth None Delayed OC
9 EL identification Type II EL Embolization
10 AAA growth Type II EL Embolization
AAA growth Type III EL Iliac endocuff
11 AAA growth None Iliac endocuff
AAA growth None
AAA growth Infection Endograft explant/
EAB
12 EL identification Type II EL
EL identification/
attempted
embolization
Type II EL Laparoscopic IMA
ligation
13 EL identification Type II EL Embolization
AAA,Abdominal aortic aneurysm;OC, open conversion; EL, endoleak; EC,
endocuff; IMA, inferior mesenteric artery; EAB, extra-anatomic bypass.EVAR ($19,985) than open AAA repair ($12,546).4 For
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high cost of the device, which accounted for50% of total
hospital expense. Similarly, others5-8 have also found that
the initial cost of EVAR exceeds that of open repair. Any
potential financial advantage of EVAR from reduced length
of stay or decreased perioperative morbidity is therefore
eliminated by the device cost. Hopeful expectation that
device costs would decrease after widespread adoption of
EVAR and increased competition has yielded to realistic
acknowledgement of persistently high and escalating device
costs.
The present study demonstrates that the $11,351 post-
placement cost of EVAR during a 5-year period increases
the global cost by 44% when added to the $19,985 implan-
tation cost4 converted to 2006 dollars.16 The largest driver
of these costs was secondary procedures, accounting for
57.4% of the total postplacement costs. Patients who re-
quired a secondary procedure had an 8.6-fold increase in
5-year cumulative mean cost of $31,696 compared with
$3668 for those who did not. In those patients without
secondary procedures, their 5-year cost ($3668) increased
the global cost by only 14%. Patients with an endoleak had
5-year postplacement costs that were 4.7-fold higher than
those with no endoleak ($26,739 vs $5706). As such, the
most effective way to reduce postplacement cost would be
to minimize the need for secondary procedures.
Over time, the postplacement costs for EVAR accumu-
late, largely as a result of vigilant monitoring and late
secondary procedures. Few studies,17-20 however, have in-
vestigated the postplacement expense for EVAR. Prinssen
et al17 studied 77 patients after EVAR performed primarily
with the Ancure device, with mean follow-up of 19.9
months. Cost of follow-up was estimated from procedural
costs in the literature and the authors’ frequency of surveil-
lance and secondary procedures. Their estimated postplace-
ment costs were $3631 at 1 year and $9729 at 5 years. An
Australian series18 examined all follow-up costs in 54 pa-
tients with a median 12 months’ follow-up. After conver-
sion to US dollars, average postplacement cost was $999
per year.
The results of our current study parallel those of the
Table IV. Postplacement costs in patients with no
endoleak versus patients with endoleak
Follow-up year
Patients with
no endoleak*
Patients with
endoleak*
No. Mean cost No. Mean cost
1 109 $2297  $615 27 $4668  $1253†
2 77 $569  $74 21 $4607  $1851
3 50 $1715  $698 15 $3836  $1986
4 35 $567  $59 12 $5043  $2171
5 22 $558  $77 11 $8585  $4797
Cumulative cost $5706 $26,739†
*Data are mean  standard error.
†Statistically significant (P  .05) vs no endoleak group.previous studies but also add significantly to the under-standing of long-term cost. Our cumulative cost was $2768
at 1 year and $11,351 at 5 years, similar to the findings of
Prinnsen et al.17 The higher cost in our study compared
with the Hayter et al18 study likely relates to our longer
follow-up (mean, 34.7 months) and the larger number of
patients. We captured a large number of costly late second-
ary procedures, 43% (n  22) of which occurred 3 to 5
years postplacement. In addition, higher overhead costs in
the United States may be a factor.21
Secondary procedures. A secondary procedure was
required in 19.9% of the cohort (n  27), and open
conversions were necessary in 4.4% (n  6). These values
are within the range reported in recent literature, with rates
as high as 27% for secondary procedures and 9% for open
conversion.11,17 In addition, to capture all costs, we
counted diagnostic angiograms as secondary procedures,
which is not uniformly done in the published reports.
Similarly, our 19.9% incidence of endoleaks corresponds
with previously reported values.22,23 These comparable
results confirm that the frequency of our largest cost gen-
erators is representative of the general post-EVAR popula-
tion.
Endoleaks alone or in conjunction with migration were
the driving force behind 56.9% of the secondary interven-
tions (n 29). Significant differences in long-term follow-up
cost between patients with andwithout secondary interven-
tion ($31,696 vs $3668) and endoleak ($26,739 vs $5706)
stress the monetary impact of late complications. Costly
late conversions comprised 12% of secondary procedures
yet accounted for 41% of late expense (Fig 2). The proce-
dural components, operative/interventional suite, and en-
dovascular materials generated 59.3% of cost of the second-
ary procedures.
Radiologic studies. Diagnostic radiologic studies for
endograft surveillance were responsible for 30% of the
long-term follow-up expense and comprised the second
largest cost component. Although surveillance schedules
vary, our protocol is a common one. Our 2006 costs were
$350 for a CT of the abdomen and pelvis, $70 for duplex
ultrasound imaging, and $51 for four-view abdominal ra-
diographs. Although the cost per study is not large, ex-
penses accumulate rapidly due to volume. A decrease in the
frequency of postplacement CT or use of a different mo-
dality could reduce this large radiology expense. However,
safe minimization of post-EVAR imaging will first require a
reduction in complications and secondary interventions.
Alternative methods of postprocedure monitoring provide
another avenue for cost reduction.
Although color flow duplex ultrasound lacks the sensi-
tivity of CT in endoleak detection,24 contrast-enhanced
ultrasound imaging may provide improved detection.25
Unfortunately, the expense of ultrasound contrast agents
and the inability to evaluate migration potentially limits its
use. Remaining cost components contributed 10.1% of the
total follow-up expense. The largest of these, outpatient
visits (7.6%), coincided with the frequency of surveillance
imaging.
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able expense to the global hospital cost of EVAR.However,
this does not mean EVAR lacks societal cost-effectiveness.
Patel et al,26 and Bosch et al,27 using Markov decision
analysis models, found EVAR to be a cost-effective alterna-
tive to open repair. Both of these analyses included cost of
follow-up. Critical to societal cost-effectiveness is mainte-
nance of low morbidity and mortality rates26 and long-term
failure and rupture rates.27
Study limitations. This study has certain limitations.
First, most patients did not have complete follow-up in
which all outpatient visits and surveillance imaging oc-
curred according to the strict surveillance protocol. There-
fore, the calculated cost does not reflect all of the potential
postplacement expenses that could be incurred in a
“model” patient. Our data more accurately represent a
realistic cross-section of postplacement follow-up, and
therefore, our determined costs are potentially less than
those obtained when follow-up is complete.
Second, the absence of those patients lost to follow-up
should not affect the results. All costs were given as per
patient with follow-up. Thus, there should be no change in
mean per patient costs, unless those patients had a different
postplacement history.
As a single institution costing analysis, costs such as
overhead and labor may vary regionally or be hospital
specific. As a retrospective study, follow-up practice pat-
terns and expenses included in the early experience with
endografts, such as surveillance ankle-brachial indices, are
no longer used. As a consequence, current yearly postplace-
ment costs are potentially lower. It is also possible that our
use of diagnostic angiograms was more aggressive in our
earlier experience. Nonetheless, most angiograms yielded a
positive result, and furthermore, with exclusion of the first
50 patients in our series, it is unlikely that a learning curve
issue was a significant factor in the cost differences. Our
study did not compare long-term postplacement costs of
EVAR with open repair. Follow-up costs of open repair
may be less, as late graft-related complications are less
frequent13 and long-term surveillance is not typically re-
quired.
Finally, there are limitations to the cost data. The
assigned institutional overhead cost factor is an estimated
fluctuating value that varies a percentage or two monthly.
In addition, the cost of professional fees was determined
by using a cost-to-charge ratio. Although this is a well-
characterized method of estimating costs, it is ultimately
based on charges, not underlying cost. These potential
areas of subtle cost alterations are unlikely to have affected
the larger trends and values seen in our cost analysis.
CONCLUSION
Long-term postplacement costs increase the global cost
of EVAR by 44% during a 5-year period. Secondary proce-
dures have the greatest impact on this cost, and when
combined with surveillance imaging expenses, account for
89.9% of postplacement cost. A disproportionate amount
of postplacement expense results from the subgroups ofpatients with secondary procedures or endoleaks. Long-
term postplacement costs will continue to increase with
continued surveillance and treatment for late complications
such as endoleak and migration. To minimize postplace-
ment costs, efforts should be directed to the device and
technical modifications that will decrease endoleaks and the
need for secondary procedures.
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This report constitutes a best-guess snapshot of costs incurred
during the rapid evolution of practice norms for endovascular
aneurysm repair (EVAR) placement and follow-up. Averaging
costs for postoperative protocol compliance between 1999 and
2006, given multiple device upgrades, steady improvement in
computed tomography (CT)-based image quality (20 catheter-
based angiograms were performed for endoleak analysis in this
study), better understanding of the significance and natural history
of type II endoleaks, and better options for secondary intervention
(eg, CT-guided glue or thrombin injection) is misleading and
likely overestimates the essential underlying cost of contemporary
long term EVAR patient management. The first 50 patients in the
Ochsner EVAR practice were excluded to minimize the cost im-
pact of the steep initial phase of the procedural learning curve;learning curve, while flatter, is undeniably longer. And, even
prospectively acquired data does not lend itself well to standard-
ization during retrospective analysis (eg, “additional studies were
left to the discretion of the individual surgeon”). Nearly half of the
patients did not complete follow-up as requested. What were the
clinical consequences of these missed visits? What would it have
cost to have all 136 patients achieve recommended endpoints? Is it
possible that less rigorous follow-up for all patients would have
provided comparable outcomes at lower cost? Across the country,
secondary intervention rates are decreasing despite increasingly
aggressive EVAR patient selection. While critically important to
the future of surgical abdominal aortic aneurysmmanagement, the
challenge inherent in this analysis is the evolutionary nature of
EVAR and the applicability of historical cost data to contemporary
practice.
